NCT03071380View on ClinicalTrials.gov

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2015

Conditions

Healthy

Interventions

DRUG

Repatoxaban

1 tablet contains 10 mg rivaroxaban

DRUG

Xarelto

1 tablet contains 10 mg rivaroxaban

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

All Listed Sponsors

collaborator

Horus for Pharmaceutical Industries, Egypt

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY

NCT03071380 - Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany) | Biotech Hunter | Biotech Hunter